Cardiopulmonary Disease in Bipolar Disorder Patient with History of SJS: Evidence Based Case Report

Authors: Zuhrotun Ulya, Muchammad Syamsulhadi, Debree Septiawan

Abstract:

Patients with bipolar disorder are three times more likely to suffer cardiovascular disorders than the general population, which will influence their level of morbidity and rate of mortality. Bipolar disorder also affects the pulmonary system. The choice of long term-monotherapy and other combinative therapies have clinical impacts on patients. This study investigates the case of a woman who has been suffering from bipolar disorder for 16 years, and who has a history of Steven Johnson Syndrome. At present she is suffering also from cardiovascular and pulmonary disorder. An analysis of the results of this study suggests that there is a relationship between cardiovascular disorder, drug therapies, Steven Johnson Syndrome and mood stabilizer obtained from the PubMed, Cochrane, Medline, and ProQuest (publications between 2005 and 2015). Combination therapy with mood stabilizer is recommended for patients who do not have side effect histories from these drugs. The replacement drugs and combinations may be applied, especially for those with bipolar disorders, and the combination between atypical antipsychotic groups and mood stabilizers is often made. Clinicians, however, should be careful with the patients’ physical and metabolic changes, especially those who have experienced long-term therapy and who showed a history of Steven Johnson Syndrome (for which clinicians probably prescribed one type of medicine).

Keywords: Cardio-pulmonary disease, bipolar disorder, Steven Johnson Syndrome, therapy.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1125917

References:

[1] Carliner, H., Collins, P. Y., Cabassa, L. J., McNallen, A., Joesti, S. S., & Fernandez, R. L. (2014). Prevalence of Cardiovascular Risk Factors among Racial and Ethnic Minorities with Schizophrenia Spectrum and Bipolar Disorders : a Critical Literature Review. Compr Psychiatry, 233-247.
[2] Fiedorowicz, J. G., He, J., & Merikangas, K. R. (2011). The Association between Mood and Anxiety Disorders with Vascular Diseases and Risk Factors in a Nationally-representative Sample. Journal Psychosomatic Research, 145-154.
[3] Simon, G. E., Von, K. M., Saunders, K., Miglioretti, D. L., Crane, P. K., & Van, B. G. (2006). Association between Obesity and Psychiatric Disorders in the US Adult Population. Arch Gen Psychiatry, 824-830.
[4] Crump, C., Sundquist, K., Winkleby, M. A., & Sundquist, J. (2013). Comorbidities and Mortality in Bipolar Disorder A Swedish National Cohort Study. JAMA Psychiatry, 931-939.
[5] Bae, H. M., Park, Y. J., Kim, Y. H., & Moon, D. E. (2013). Stevens-Johnson Syndrome Induced by Carbamazepine Treatment in a Patient Who Previously Had Carbamazepine Induced Pruritus - A Case Report -. The Korean Journal of Pain, 80-83.
[6] Ulya, Z., Syamsulhadi, M., Herdaetha, A., Septiawan, D. Gangguan Kardiovaskuler pada Pasien Gangguan Bipolar: Laporan Kasus. Unpublished.
[7] Smith, D. J., Martin, D., McLean, G., Langan, J., Guthrie, B., & Mercer, S. W. (2013). Multimorbidity in Bipolar Disorder and Undertreatment of Cardiovascular Disease : a Cross Sectional Study. BMC Medicine, 1-11.
[8] Thomas, T.M., Jones, M.E., Patel D., Brunner, E., Shatapahty, C.C., Motsko, S.,, & Staa, T.P. (2013). Clinical Study Risk of Mortality (ncluding Sudden Cardiac Death) and Major Cardiovascular Events in Atypical and Typical Antipsychotic Users: A Study with the General Practice Research Database. Cardiovascular Psychiatry and Neurology, 1-15.
[9] Leonard, C. E., Freeman, C. P., Newcomb, C. W., Bilker, W. B., Kimmel, S. E., Strom, B. L., & Hennessy, S. (2013). Antipsychotics and the Risks of Sudden Cardiac Death and All-Cause Death: Cohort Studies in Medicaid and Dually-Eligible Medicaid-Medicare Beneficiaries of Five States. Journal Clinical Expert Caridology, 1-9.
[10] Linder, J. R., Sodhi, S. K., Haynes, W. G., & Fiedorowicz, J. G. (2014). Effects of Antipsychotic Drugs on Cardiovascular Variablity in Participants with Bipolar Disorder. Hum Psychopharmacol, 145-151
[11] Azcurra, D. J. L. S. (2013). Lamotrigine Rechallenge after a Skin Rash. A Combined Study of Open Cases and a Meta-analysis. Rev Psiquiatr Salud Ment, 6(4): 144-149.
[12] Fiedorowicz, J., Coryell, W., Rice, J., Warren, L., & Haynes, W. (2012). Vasculopathy Related to Manic Hypomanic Symptom Burden and First-generation Antipsychotics in a sub-sample from the Collaborative Depression Study. Psychoteraphy Psychosomatic, 235-243.
[13] Tadori, Y., Forbes, R., Mcquade, R., & Kikuchi, T. (2011). Functional Potencies of Dopamine Agonists and Antagonists at Human Dopamine D(2) and D(3) Receptors. Europe Journal Pharmacology, 43-52.
[14] Nielsen, J., Graff, C., Kanters, J., Toft, E., & Taylor, D. (2011). Assessing QT Interval Prolongation and Its Associated Risks with Antipsychotics. CNS Drugs, 25:473-490.